Sugi Predict

Sugi Predict / Targets / TPMT

TPMT

Thiopurine S-methyltransferase · P51580 · TPMT on Sugi Atlas →

21,938 patent compounds predicted against TPMT, 15,037 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL312132 SCHEMBL312132 0.55 7/20
SCHEMBL503998 SCHEMBL503998 1.00 6/20
SCHEMBL56960 SCHEMBL56960 0.68 6/20
SCHEMBL289536 SCHEMBL289536 0.53 6/20
SCHEMBL122324 SCHEMBL122324 1.00 5/20
3,4,5-Trimethoxybenzoic Acid 3,4,5-Trimethoxybenzoic Acid (SCHEMBL6592) 0.78 5/20
SCHEMBL422824 SCHEMBL422824 0.59 5/20
SCHEMBL39734 SCHEMBL39734 0.48 5/20
SCHEMBL419090 SCHEMBL419090 0.46 5/20
SCHEMBL498268 SCHEMBL498268 0.48 4/20
SCHEMBL8361 SCHEMBL8361 0.48 4/20
SCHEMBL475757 SCHEMBL475757 0.48 4/20
SCHEMBL56890 SCHEMBL56890 0.46 4/20
SCHEMBL419245 SCHEMBL419245 0.43 4/20
SCHEMBL68928 SCHEMBL68928 0.42 4/20
SCHEMBL200289 SCHEMBL200289 0.41 4/20
SCHEMBL342923 SCHEMBL342923 0.38 4/20
SCHEMBL342924 SCHEMBL342924 0.38 4/20
SCHEMBL23699 SCHEMBL23699 1.00 3/20
SCHEMBL221684 SCHEMBL221684 1.00 3/20

Clinical trials — most relevant to TPMT by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Influence of 5-Aminosalicylates on Thiopurine Metabolite Levels PHASE4COMPLETED
Reduce Risk for Crohn's Disease Patients PHASE4COMPLETED
Effect of Intravenous (IV) Vedolizumab on Mucosal Healing in Crohn's Disease PHASE3COMPLETED
Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia PHASE3COMPLETED
Beneficial and Harmful Effects of Azathioprine and Allopurinol Versus Standard Azathioprine Therapy for Patients With Ulcerative Colitis PHASE3UNKNOWN
Study of 6-Thioguanine in Combination With 6-Mercaptopurine During Maintenance Therapy of Childhood Lymphoma PHASE1/PHASE2WITHDRAWN
A Clinical Trial in Patients With Breast Cancer Susceptibility Gene (BRCA) Defective Tumours PHASE2COMPLETED
NOPHO ALL-2008 Pilot Study on Consolidation Therapy for Children and Adolescents With Acute Lymphoblastic Leukemia PHASE2COMPLETED
A Randomized Multicenter Study for Isolated Skin Vasculitis PHASE2RECRUITING
Optimizing 6-mercaptopurine Therapy in Pediatric Acute Lymphoblastic Leukemia by Using Allopurinol PHASE2UNKNOWN
Treatment of Granulomatous and Lymphocytic Interstitial Lung Disease in Patients With Common Variable Immunodeficiency PHASE2WITHDRAWN
Bioequivalence of An Oral Mercaptopurine Suspension 100 Mg / 5 Ml Versus Tablet in Healthy Male Subjects Under Fasting Conditions PHASE1COMPLETED
Azathioprine & Allopurinol in Inflammatory Bowel Disease Patients PHASE1COMPLETED
Pilot Comparative Bioavailability Study of 6Mercaptopurine (Delayed Release vs. Purinethol) in Crohns Disease Patients PHASE1COMPLETED
An EQA Scheme for TPMT Activity and Thiopurine Metabolites nanUNKNOWN
Functional Pharmacogenomics of Childhood Acute Lymphoblastic Leukemia in Taiwan nanUNKNOWN
Thiopurine Methyltransferase Polymorphisms Evaluation nanWITHDRAWN
Correlation of Genetic Polymorphism of Azathioprine Metabolizing Enzymes and Correlation to Clinical Adverse Effects nanCOMPLETED
Pharmacogenetically Based Dosing of Thiopurines in Childhood Acute Lymphoblastic Leukemia nanCOMPLETED
Cost-effectiveness of TPMT Pharmacogenetics nanCOMPLETED
The Influence of Thiopurine Methyltransferase Activity on Toxicity After High-dose Methotrexate in Childhood Acute Lymphoblastic Leukemia nanCOMPLETED
Bioequivalence Study of 6-Mercaptopurine Under Fasting Conditions nanCOMPLETED
The Frequency of Thiopurine Methyltransferase Polymorphism in Systemic Lupus Erythematosus SLE nanCOMPLETED
Tailored Therapeutic Model According to the Expression of Genes in Inflammatory Bowel Disease Patients nanCOMPLETED
Genetic Polymorphisms in Drug Induced Neuropathy in Children With ALL nanUNKNOWN
Pre-genotype NUDT 15 R139C on Reducing Thiopurine-induced Leucopenia in Inflammatory Bowel Disease nanUNKNOWN
Biobank - Investigating the Gut Microbiota, Genetics, Epigenetics and Metabolites nanRECRUITING
Immunogenicity of COVID-19 Vaccine in Patients With Inflammatory Bowel Disease nanCOMPLETED
IBD Self-management Website and Home Faecal Calprotectin Monitoring nanCOMPLETED
The Impact of 6MP Metabolite Levels on Infliximab Pharmacokinetics and Anti-infliximab Antibodies in Crohn's Disease nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a TPMT binder may also engage these)

ProteinNameSimilarity
Q3BCR3 — 1.000 Q3BCR3 →
Q3BCR8 — 1.000 Q3BCR8 →
Q6EIC1 — 1.000 Q6EIC1 →
Q3BCR0 — 1.000 Q3BCR0 →
Q17QQ2 — 1.000 Q17QQ2 →
Q8HX86 — 0.999 Q8HX86 →
Q3BCR5 — 0.999 Q3BCR5 →
Q3BCR6 — 0.997 Q3BCR6 →
Q5RBJ3 — 0.997 Q5RBJ3 →
Q3BCR9 — 0.997 Q3BCR9 →
Q3BCR4 — 0.996 Q3BCR4 →
Q9Z0T0 — 0.995 Q9Z0T0 →
Q9QX22 — 0.995 Q9QX22 →
Q3BCR1 — 0.995 Q3BCR1 →
Q3BCQ8 — 0.993 Q3BCQ8 →
Q3BCR2 — 0.990 Q3BCR2 →
O55060 — 0.990 O55060 →
Q504A5 — 0.988 Q504A5 →
Q6NTR1 — 0.969 Q6NTR1 →
E1BVR9 — 0.969 E1BVR9 →
Q5T8I9 — 0.967 Q5T8I9 →
Q4R3W5 — 0.966 Q4R3W5 →
NNMT Nicotinamide N-methyltransferase 0.966 landscape →
O55239 — 0.966 O55239 →
F4IVI0 — 0.965 F4IVI0 →
Q06AV1 — 0.965 Q06AV1 →
Q4KLT3 — 0.965 Q4KLT3 →
O97972 — 0.964 O97972 →
C0IN03 — 0.964 C0IN03 →
Q9UIC8 — 0.964 Q9UIC8 →